Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Get Rating) Executive Vice Chairman Kim Sablich sold 1,388 shares of the company in a trade on Monday, June 6. The shares were sold at an average price of $152.15, for a total transaction of $211,184.20. Following the completion of the transaction, the executive vice president now owns 27,195 shares of the company, valued at approximately $4,137,719.25. The sale was disclosed in a filing with the SEC, which is available at this link.
The NASDAQ JAZZ traded at $2.96 on Wednesday, hitting $151.61. 466,804 shares were traded, against an average volume of 598,185. The company has a 50-day moving average price of $155.72 and a 200-day moving average price of $144.58. Jazz Pharmaceuticals plc has a fifty-two week low of $117.64 and a fifty-two week high of $189.00. The company has a quick ratio of 2.06, a current ratio of 3.39 and a debt ratio of 1.66. The company has a market capitalization of $9.45 billion, a PE ratio of -20.58, a PEG ratio of 1.24 and a beta of 0.80.
Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Rating) last reported quarterly results on Wednesday, May 4. The specialty pharmaceutical company reported earnings per share (EPS) of $3.13 for the quarter, beating consensus analyst estimates of $3.00 by $0.13. Jazz Pharmaceuticals posted a negative net margin of 13.63% and a positive return on equity of 22.45%. The company posted revenue of $813.72 million in the quarter, versus a consensus estimate of $853.73 million. In the same quarter last year, the company posted EPS of $3.42. The company’s revenues increased by 33.9% compared to the same quarter last year. As a group, equity research analysts expect Jazz Pharmaceuticals plc to post EPS of 14.73 for the current financial year.
JAZZ has been the subject of several research reports. BMO Capital Markets cut its price target on shares of Jazz Pharmaceuticals from $202.00 to $187.00 in a Wednesday, March 2 report. StockNews.com upgraded Jazz Pharmaceuticals from a “hold” rating to a “buy” rating in a Thursday, June 2 research note. HC Wainwright raised its target price on Jazz Pharmaceuticals from $210.00 to $215.00 and gave the stock a “buy” rating in a Thursday, March 3 report. Cowen raised his target price on Jazz Pharmaceuticals from $200.00 to $225.00 in a Thursday, May 5 research note. Finally, Cantor Fitzgerald reiterated an “overweight” rating on Jazz Pharmaceuticals shares in a Wednesday, March 2 research note. Three equity research analysts gave the stock a hold rating and ten gave the company a buy rating. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $206.47.
Hedge funds have recently increased or reduced their stakes in the company. The Kentucky State Teachers’ Retirement System increased its stake in shares of Jazz Pharmaceuticals by 8.8% in the first quarter. The Kentucky State Teachers’ Retirement System now owns 69,912 shares of the specialty pharmaceutical company valued at $10,883,000 after buying an additional 5,679 shares last quarter. Bank of America Corp DE increased its stake in Jazz Pharmaceuticals by 18.7% in the first quarter. Bank of America Corp DE now owns 301,951 shares of the specialty pharmaceutical company valued at $47,004,000 after acquiring 47,553 additional shares in the last quarter. Neuberger Berman Group LLC increased its stake in shares of Jazz Pharmaceuticals by 51.2% in the first quarter. Neuberger Berman Group LLC now owns 5,186 shares of the specialty pharmaceutical company worth $807,000 after buying 1,755 additional shares in the last quarter. Greylin Investment Management Inc. increased its stake in shares of Jazz Pharmaceuticals by 24.2% in the first quarter. Greylin Investment Management Inc. now owns 4,340 shares of the specialty pharmaceutical company worth $676,000 after buying 846 additional shares in the last quarter. Finally, The Manufacturers Life Insurance Company increased its position in Jazz Pharmaceuticals by 89.2% during the first quarter. The Manufacturers Life Insurance Company now owns 129,235 shares of the specialty pharmaceutical company worth $20,184,000 after acquiring an additional 60,938 shares during the period. 93.23% of the shares are held by institutional investors and hedge funds.
About Jazz Pharmaceuticals (Get an evaluation)
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops and markets pharmaceutical products for a variety of unmet medical needs in the United States, Europe and globally. The Company has a portfolio of products and product candidates focused on areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors.
Featured articles
Get news and reviews for Jazz Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com’s free daily email newsletter.
